Detection of anticoagulant activities of isolated canine fibrinogen degradation products X, Y, D and E using resonance thrombography

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 1, 2004, Pages 81-88

  Mischke, Reinhard ^a   Wolling, Hermann ^a   Nolte, Ingo ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Anticoagulant effect; Dog; Fibrinogen degradation products; Resonance thrombography

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN DEGRADATION PRODUCT;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; FEMALE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; REACTION TIME; RESONANCE THROMBOGRAPHY; SCREENING TEST;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOGS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS;

EID: 2042481386     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200401000-00013     Document Type: Article

References (24)

1. Hartert H. Resonance-thrombography: theoretical and practical elements. Biorheology 1981; 18:693-701.
2. Hartert H. The proper phase of coagulation: its physical differentiation by resonance-thrombography and thrombelastography. Clin Hemorheol 1982; 2:51-69.
3. Hartert H. Differenzierung der Therapie von Gerinnungsstörungen durch Diagnostik mit dem Resonanzthrombographen. Therapiewoche 1983; 33:4626-4634.
4. Hartert H. Biorheology in the practice of medicine: resonance thrombography. Biorheology 1984; 21:19-32.
5. Geiss V, Geiss B, Nolte I. Hämostasestörungen bei malignen Hämangioendotheliomen und Leukosen des Hundes - Aussagen der Resonanz-thrombographie. Tierärztl Prax Suppl 1989; 5:68-71.
6. Hinsenbrock K-P, Anders O, Ernst B, Neumann B, Förster J. Hämostaseologisches Monitoring in der Intensivtherapie: Untersuchungen mittels Resonanzthrombographie. Anaesthesiol Reanimat 1989; 14:219-225
7. Mischke R, Nolte I. Labordiagnostik und Differentialdiagnose der Verbrauchskoagulopathie beim Hund. Berl Münch Tierärztl Wochenschr 1992; 105:401-410.
8. Anders O, Görss E-W, Ernst B, Konrad H. Erfassung des Faktor-XIII-Mangels bei akuter Leukämie mit der Resonanzthrombographie. Folia Haematol 1987; 114:670-679.
9. Wolling H, Mischke R. Präparation und Reinigung von Milligramm-Mengen der caninen Fibrinogenspaltprodukte (FSP) -X, -Y, -D und -E. Berl Münch Tierärztl Wochenschr 1995; 108:421-426.
10. Kazal LA, Amsel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113:989-994.
11. Heukeshoven J, Dernick R. Improved silver staining procedure for fast staining in Phast system development unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 1988; 9:28-32.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
13. Mischke R, Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis 2000; 30:123-130.
14. Mischke R. Sensitivity of reaction time of the resonance thrombogram for factor VIII:C and factor IX deficiencies in the blood of dogs with haemophilia A or B. Haemophilia 2000; 6:575-580.
15. Mischke R, Adamik A. Sensitivität des Resonanzthrombogramms bei der Thrombozytopenie des Hundes. Berl Münch Tierärztl Wochenschr 1998; 111:302-305.
16. Haverkate F, Timan G, Nieuwenhuizen W. Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 1979; 9:253-255.
17. Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin: II. Mechanism of their anticoagulant activity. J Biol Chem 1969; 244:2120-2124.
18. Nieuwenhuizen W, Voskuilen M, Hermanns J. Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen (plasmin fragments Y). Biochem Biophys Acta 1982; 708: 313-316.
19. Chen JP, Hutchison HAT, Nanninga LB, Mason Guest M. Characterization of the terminal degradation products of canine fibrinogen by plasmin. Biochem Biophys Acta 1975; 386:66-79.
20. Larrieu MJ, Rigollot C, Marder VJ. Comparative effects of fibrinogen degradation fragments D and E on coagulation. Br J Haematol 1972; 22:729-733.
21. Latallo ZS, Budzynski AZ, Lipinski B, Kowalsi E. Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 1964; 203:1184-1185.
22. Gaffney PJ. Fibrin(-ogen) interactions with plasmin. Haemostasis 1977; 6:2-25.
23. Marder VJ, Shulman NR. High molecular weight derivatives of human plasmin produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969; 244:2111-2119.
24. Birken S, Wilner GD, Canfield RE. Studies of the structure of canine fibrinogen. Thromb Res 1975; 7:599-610.